These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30318139)

  • 1. New joint consensus initiative on quantifying atherogenic lipoproteins.
    Stock JK
    Atherosclerosis; 2018 Dec; 279():97-99. PubMed ID: 30318139
    [No Abstract]   [Full Text] [Related]  

  • 2. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 3. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
    Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
    Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LDL/apo B ratio predict coronary heart disease in Type 2 diabetes independent of ASCVD risk score: A case-cohort study.
    Rabizadeh S; Rajab A; Mechanick JI; Moosaie F; Rahimi Y; Nakhjavani M; Esteghamati A
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1477-1485. PubMed ID: 33810957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can We Cure Atherosclerosis?
    Robinson JG; Davidson MH
    Rev Cardiovasc Med; 2018; 19(S1):S20-S24. PubMed ID: 30207554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study.
    Dusejovska M; Stankova B; Vecka M; Rychlíkova J; Mokrejsova M; Rychlík I; Zak A
    Curr Vasc Pharmacol; 2018; 16(3):298-305. PubMed ID: 28554308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoB.
    Sniderman AD; Pencina M; Thanassoulis G
    Circ Res; 2019 May; 124(10):1425-1427. PubMed ID: 31070997
    [No Abstract]   [Full Text] [Related]  

  • 9. Should advanced lipoprotein testing be used in clinical practice?
    Stein JH; McBride PE
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):640-1. PubMed ID: 17122792
    [No Abstract]   [Full Text] [Related]  

  • 10. What is 'LDL cholesterol'?
    Holmes MV; Ala-Korpela M
    Nat Rev Cardiol; 2019 Apr; 16(4):197-198. PubMed ID: 30700860
    [No Abstract]   [Full Text] [Related]  

  • 11. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of lecithin-cholesterol acyltransferase activity and low-density lipoprotein heterogeneity with atherosclerotic cardiovascular disease risk: a longitudinal pilot study.
    Yokoyama K; Tani S; Matsuo R; Matsumoto N
    BMC Cardiovasc Disord; 2018 Dec; 18(1):224. PubMed ID: 30518338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study.
    Ren XY; Shi D; Ding J; Cheng ZY; Li HY; Li JS; Pu HQ; Yang AM; He CL; Zhang JP; Ma YB; Zhang YW; Zheng TZ; Bai YN; Cheng N
    Lipids Health Dis; 2019 Feb; 18(1):47. PubMed ID: 30744645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
    Carr SS; Hooper AJ; Sullivan DR; Burnett JR
    Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
    Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG;
    Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History of lipidology and lipoprotein apheresis.
    Julius U
    Atheroscler Suppl; 2017 Nov; 30():1-8. PubMed ID: 29096824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse lipid profile elevates risk for subarachnoid hemorrhage: A prospective population-based cohort study.
    Lindbohm J; Korja M; Jousilahti P; Salomaa V; Kaprio J
    Atherosclerosis; 2018 Jul; 274():112-119. PubMed ID: 29772479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile.
    Kaneva AM; Potolitsyna NN; Bojko ER
    Arch Physiol Biochem; 2017 Feb; 123(1):16-22. PubMed ID: 27347637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.